Zisman Erin, Bashir-Hamidu Rukaiya, George Lauren
Department of Medicine, Division of Gastroenterology and Hepatology, University of Maryland Medical System, Baltimore, MD.
ACG Case Rep J. 2024 Sep 27;11(10):e01528. doi: 10.14309/crj.0000000000001528. eCollection 2024 Oct.
Tofacitinib is a Janus kinase inhibitor commonly used in the management of rheumatoid arthritis and moderate-to-severe ulcerative colitis. Anemia is a rare side effect of this medication often with minimal changes in hemoglobin levels. We report the first case of autoimmune hemolytic anemia from tofacitinib use in a patient with inflammatory bowel disease. This patient developed transfusion-dependent anemia after the initiation of tofacitinib and underwent extensive workup that revealed a diagnosis of autoimmune hemolytic anemia. The medication was discontinued, and she was treated with steroids and rituximab, leading to the improvement and stabilization of her hemoglobin levels.
托法替布是一种常用的 Janus 激酶抑制剂，用于治疗类风湿性关节炎和中度至重度溃疡性结肠炎。贫血是这种药物罕见的副作用，通常血红蛋白水平变化极小。我们报告了第一例炎症性肠病患者使用托法替布后发生自身免疫性溶血性贫血的病例。该患者在开始使用托法替布后出现依赖输血的贫血，并接受了全面检查，结果诊断为自身免疫性溶血性贫血。停用该药物后，她接受了类固醇和利妥昔单抗治疗，血红蛋白水平得到改善并稳定。
